NCT00096850View on ClinicalTrials.gov

Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults

NACompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

Not specified

Study Completion Date

December 31, 2007

Conditions
HIV InfectionsTuberculosis
Interventions
DRUG

Atazanavir

From Days 9 to 19, participants will receive a 300 mg tablet orally daily. From Days 20 to 27, participants will receive a 400 mg tablet orally daily.

DRUG

Rifampin

From Days 1 to 27, participants will receive a 600 mg tablet orally daily.

DRUG

Ritonavir

From Days 9 to 19, participants will receive a 100 mg tablet orally daily. From Days 20 to 27, participants will receive a 100 mg tablet orally twice daily.

Trial Locations (3)

37203

Vanderbilt Therapeutics CRS, Nashville

43210

The Ohio State Univ. AIDS CRS, Columbus

94305-5107

Stanford CRS, Palo Alto

All Listed Sponsors
collaborator

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00096850 - Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults | Biotech Hunter | Biotech Hunter